CD274 and congenital rubella syndrome: An important advantage of CAR exosomes over cell therapy is their enhanced safety profile: they do not express inhibitory receptors such as PD-1, which makes their cytotoxic effect resistant to the immunosuppressive influence of the PD-L1 ligand, and they also do not cause cytokine release syndrome (CRS) in preclinical model [69].